<p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）在周四早上发布了 2026 财年的收益指引更新。该公司提供的每股收益（EPS）指引为 4.700-5.00，而市场共识预期为 4.866。该公司发布的收入指引为-。</p>
<h2>Haemonetics 股票表现</h2>
<p>周四，纽约证券交易所 HAE 的股票开盘价为 75.81 美元。该公司的 50 日简单移动平均为 73.24 美元，200 日简单移动平均为 67.65 美元。该股票的市值为 36.4 亿美元，市盈率为 22.90，PEG 比率为 1.23，贝塔值为 0.40。该公司的流动比率为 1.62，速动比率为 0.99，债务股本比率为 1.12。Haemonetics 的 12 个月低点为 55.30 美元，12 个月高点为 94.99 美元。</p>
<p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）最近一次发布财报是在 8 月 7 日，周四。该医疗仪器供应商报告的每股收益（EPS）为 1.10 美元，超出分析师共识预期的 1.02 美元，超出幅度为 0.08 美元。Haemonetics 的净利润率为 12.32%，股本回报率为 26.37%。整体来看，分析师预测 Haemonetics 在当前年度的每股收益将为 4.55 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>HAE 近期成为几份研究报告的主题。Raymond James Financial 在 5 月 9 日的研究报告中重申了对 Haemonetics 的 “强烈买入” 评级，并将目标价设定为 105.00 美元（低于 115.00 美元）。花旗集团在 7 月 9 日的报告中将 Haemonetics 的评级从 “中性” 上调至 “买入”，并设定目标价为 90.00 美元。Needham &amp; Company LLC 在 5 月 8 日的研究报告中将 Haemonetics 的目标价从 104.00 美元下调至 84.00 美元，并对该股票给予 “买入” 评级。Robert W. Baird 在 6 月 26 日的报告中开始覆盖 Haemonetics，并设定了 “跑赢大盘” 评级和 87.00 美元的目标价。最后，Baird R W 在 6 月 25 日的研究报告中将 Haemonetics 的评级上调至 “强烈买入”。一位股票研究分析师给予该股票 “卖出” 评级，一位给予 “持有” 评级，八位给予 “买入” 评级，两位给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，Haemonetics 的平均评级为 “适度买入”，共识目标价为 97.30 美元。</p>
<p><strong>查看我们关于 Haemonetics 的最新研究报告</strong></p>
<h2>机构投资者对 Haemonetics 的看法</h2>
<p>几家对冲基金和其他机构投资者最近购买和出售了该公司的股票。Strs Ohio 在第一季度购买了 Haemonetics 的新股份，价值约为 140,000 美元。美国联合服务汽车协会在第一季度购买了 Haemonetics 的新股份，价值约为 212,000 美元。Caxton Associates LLP 在第一季度收购了 Haemonetics 的新股份，价值约为 216,000 美元。Empowered Funds LLC 在第一季度将其在 Haemonetics 的持仓提高了 9.1%。Empowered Funds LLC 现在拥有 Haemonetics 的 4,458 股股票，价值 283,000 美元，此前在上个季度又购买了 372 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Haemonetics 的股份增加了 3.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 Haemonetics 的 29,541 股股票，价值 1,877,000 美元，此前在此期间又购买了 971 股。目前 99.67% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Haemonetics</h2>
<p>（获取免费报告）</p>
<p>Haemonetics Corporation 是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件以及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关一次性用品和解决方案，以及集成的信息技术平台，供血浆客户管理其捐赠者、运营和供应链；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Haemonetics 更好</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>回购股票而非分红？这两只股票选择提供了强有力的理由</li>
<li>如何投资蓝筹股</li>
<li>Navitas 股票的下跌：是经过深思熟虑的风险还是明确的买入信号？</li>
<li>什么是空头头寸？如何使用它</li>
<li>买入下跌？这些收益未达预期的股票提供了长期上涨的潜力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Haemonetics 吗？</h2>
<p>在考虑 Haemonetics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Haemonetics 并不在名单上。</p>
<p>虽然 Haemonetics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

<p>海蒙尼克斯（NYSE:HAE）更新了其 2026 财年的收益指引，预计每股收益在 4.700 到 5.00 之间，略高于市场共识预期的 4.866。该公司的股票开盘价为 75.81 美元，市值为 36.4 亿美元。分析师的评级不一，市场共识目标价为 97.30 美元。机构投资者持有 99.67% 的股份。海蒙尼克斯专注于医疗产品和解决方案，包括自动化血浆采集系统和献血者管理软件</p>

<p>Haemonetics (NYSE:HAE - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.700-5.00 for the period, compared to the consensus estimate of 4.866. The company issued revenue guidance of -.</p>
<div class="lb-trans"><p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）在周四早上发布了 2026 财年的收益指引更新。该公司提供的每股收益（EPS）指引为 4.700-5.00，而市场共识预期为 4.866。该公司发布的收入指引为-。</p>
</div><h2>Haemonetics Stock Performance</h2>
<div class="lb-trans"><h2>Haemonetics 股票表现</h2>
</div><p>Shares of NYSE HAE opened at $75.81 on Thursday. The company has a 50 day simple moving average of $73.24 and a two-hundred day simple moving average of $67.65. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 1.23 and a beta of 0.40. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Haemonetics has a 12 month low of $55.30 and a 12 month high of $94.99.</p>
<div class="lb-trans"><p>周四，纽约证券交易所 HAE 的股票开盘价为 75.81 美元。该公司的 50 日简单移动平均为 73.24 美元，200 日简单移动平均为 67.65 美元。该股票的市值为 36.4 亿美元，市盈率为 22.90，PEG 比率为 1.23，贝塔值为 0.40。该公司的流动比率为 1.62，速动比率为 0.99，债务股本比率为 1.12。Haemonetics 的 12 个月低点为 55.30 美元，12 个月高点为 94.99 美元。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.08. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. As a group, analysts predict that Haemonetics will post 4.55 earnings per share for the current year.</p>
<div class="lb-trans"><p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）最近一次发布财报是在 8 月 7 日，周四。该医疗仪器供应商报告的每股收益（EPS）为 1.10 美元，超出分析师共识预期的 1.02 美元，超出幅度为 0.08 美元。Haemonetics 的净利润率为 12.32%，股本回报率为 26.37%。整体来看，分析师预测 Haemonetics 在当前年度的每股收益将为 4.55 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>HAE has been the subject of several recent research reports. Raymond James Financial reiterated a &#34;strong-buy&#34; rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Citigroup raised shares of Haemonetics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $90.00 target price for the company in a report on Wednesday, July 9th. Needham &amp; Company LLC dropped their price target on shares of Haemonetics from $104.00 to $84.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, May 8th. Robert W. Baird initiated coverage on Haemonetics in a report on Thursday, June 26th. They set an &#34;outperform&#34; rating and a $87.00 target price for the company. Finally, Baird R W raised Haemonetics to a &#34;strong-buy&#34; rating in a research note on Wednesday, June 25th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $97.30.</p>
<div class="lb-trans"><p>HAE 近期成为几份研究报告的主题。Raymond James Financial 在 5 月 9 日的研究报告中重申了对 Haemonetics 的 “强烈买入” 评级，并将目标价设定为 105.00 美元（低于 115.00 美元）。花旗集团在 7 月 9 日的报告中将 Haemonetics 的评级从 “中性” 上调至 “买入”，并设定目标价为 90.00 美元。Needham &amp; Company LLC 在 5 月 8 日的研究报告中将 Haemonetics 的目标价从 104.00 美元下调至 84.00 美元，并对该股票给予 “买入” 评级。Robert W. Baird 在 6 月 26 日的报告中开始覆盖 Haemonetics，并设定了 “跑赢大盘” 评级和 87.00 美元的目标价。最后，Baird R W 在 6 月 25 日的研究报告中将 Haemonetics 的评级上调至 “强烈买入”。一位股票研究分析师给予该股票 “卖出” 评级，一位给予 “持有” 评级，八位给予 “买入” 评级，两位给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，Haemonetics 的平均评级为 “适度买入”，共识目标价为 97.30 美元。</p>
</div><p><strong>View Our Latest Research Report on Haemonetics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Haemonetics 的最新研究报告</strong></p>
</div><h2>Institutional Investors Weigh In On Haemonetics</h2>
<div class="lb-trans"><h2>机构投资者对 Haemonetics 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of Haemonetics in the 1st quarter valued at approximately $140,000. United Services Automobile Association purchased a new stake in Haemonetics during the 1st quarter worth about $212,000. Caxton Associates LLP acquired a new stake in Haemonetics in the 1st quarter valued at about $216,000. Empowered Funds LLC raised its position in Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after purchasing an additional 372 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock valued at $1,877,000 after buying an additional 971 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近购买和出售了该公司的股票。Strs Ohio 在第一季度购买了 Haemonetics 的新股份，价值约为 140,000 美元。美国联合服务汽车协会在第一季度购买了 Haemonetics 的新股份，价值约为 212,000 美元。Caxton Associates LLP 在第一季度收购了 Haemonetics 的新股份，价值约为 216,000 美元。Empowered Funds LLC 在第一季度将其在 Haemonetics 的持仓提高了 9.1%。Empowered Funds LLC 现在拥有 Haemonetics 的 4,458 股股票，价值 283,000 美元，此前在上个季度又购买了 372 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Haemonetics 的股份增加了 3.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 Haemonetics 的 29,541 股股票，价值 1,877,000 美元，此前在此期间又购买了 971 股。目前 99.67% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Haemonetics</h2>
<div class="lb-trans"><h2>关于 Haemonetics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p>
<div class="lb-trans"><p>Haemonetics Corporation 是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件以及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关一次性用品和解决方案，以及集成的信息技术平台，供血浆客户管理其捐赠者、运营和供应链；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Buybacks Over Dividends? These 2 Stock Picks Make a Strong Case</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Navitas Stock's Dip: A Calculated Risk or a Clear Buy Signal?</li>
<li>What is Short Interest? How to Use It</li>
<li>Buy the Dip? These Earnings Misses Offer Long-Term Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Haemonetics 更好</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>回购股票而非分红？这两只股票选择提供了强有力的理由</li>
<li>如何投资蓝筹股</li>
<li>Navitas 股票的下跌：是经过深思熟虑的风险还是明确的买入信号？</li>
<li>什么是空头头寸？如何使用它</li>
<li>买入下跌？这些收益未达预期的股票提供了长期上涨的潜力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Haemonetics 吗？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Haemonetics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Haemonetics 并不在名单上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Haemonetics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Heamonetics（纽约证券交易所代码：HAE）发布 2026 财年的收益指引